NetworkNewsWire Editorial Coverage:
Hydrogels have been in limited commercial use for more than two
decades. However, advancements in drug delivery, and thus hydrogel
technology, are driving rapid growth in the global market, which is
now projected to surge to over $22 billion by 2022 with a compound
annual growth rate (CAGR) of 6.3 percent (http://nnw.fm/GWv2x), according to BCC Research. In
what may prove to be a groundbreaking approach in this field of
exponential opportunity, PreveCeutical Medical Inc. (CSE:
PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF
Profile) is engineering a unique sol-gel nose-to-brain drug
delivery platform to provide clinical relief of multiple physical
maladies. Other recognized companies that have embraced new methods
of drug delivery and hydrogel delivery systems include
Johnson & Johnson (NYSE: JNJ), Valeant Pharmaceuticals
International Inc. (VRX: NYSE), UroGen Pharma Ltd. (NASDAQ:
URGN) and GW Pharmaceuticals PLC (GWPH:
NASDAQ).
Hydrogel Market Driven by Drug Delivery
Advances
For most of modern history, pharmaceuticals have consisted of
simple, fast-acting chemical compounds administered orally or by
injection. However, the continual evolution of the understanding of
the human body has triggered an explosion of new and potentially
lifesaving treatments. These new pharmaceutical therapeutics
require revolutionary new techniques of administration. The
objective of modern drug delivery systems is to deploy medications
intact to specifically targeted parts of the body through a medium
that can control the therapy’s administration and enhance
bioavailability. To achieve this goal, researchers have turned to
advances in hydrogel materials, which have demonstrated efficacy in
enhancing drug targeting specificity by helping medications cross
the blood-brain barrier — lowering systemic drug toxicity,
improving treatment absorption rates and mitigating biochemical
degradation.
Hydrogels are three-dimensional molecular structures capable of
absorbing large amounts of water or biological fluids. Due to their
porosity and supple consistency, they closely simulate natural
living tissue — more so than any other class of synthetic
biomaterials. Their resemblance to living tissue opens vast
opportunities for applications in biomedical arenas. Currently,
hydrogels are used for manufacturing contact lenses, hygiene
products, tissue engineering scaffolds and, now, drug delivery
systems.
PreveCeutical’s Novel
Approach
PreveCeutical
Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), a preventive
health sciences company initiating a broad spectrum of preventive
and curative therapies, is engineering what it believes to be the
world’s first nose-to-brain hydrogel platform. Following several
years of research and development by PreveCeutical’s chief research
officer, Dr. Harendra Parekh, Ph.D., the company’s novel sol-gel
technology is designed for superior time-released delivery of
cannabinoid (CBD)-based medications. Bypassing typical delivery
techniques, this nasal spray formulation is meticulously engineered
to rapidly gel and deliver drugs in a controlled fashion across
target tissue, which in the case of nose-to-brain delivery is the
olfactory mucosal epithelium within the nasal cavity.
Conventional drug delivery, whether through oral or injectable
mediums, moves drugs into the bloodstream where they are then
passed through the liver. The drugs are unable to directly impact
the targeted area as the liver first filters then metabolizes the
drugs, which also affects release times and reduces potency. In a
potentially transformative technique of drug delivery,
PreveCeutical’s platform circumvents the blood-brain barrier and
liver through application directly onto nasal mucosal tissue. The
blood-brain barrier has long challenged effective medicine delivery
due to the filtering mechanism of the capillaries that carry blood
to the brain and block the passage of certain substances.
PreveCeutical’s novel sol-gel drug delivery platform is designed
for use in both children and adults. Once or twice daily dosing
should be reduced to once or twice a week with the product. The
formulation is in liquid form when it is sprayed into the nose,
then rapidly turns to a gel and is retained on the nasal mucosa.
Initially targeting cannabinoid delivery, sol-gels are a platform
that can be applied to numerous medicines for extended release and
vastly improved bioavailability.
The proprietary sol-gel formulations are anticipated to be
commercially launched with licensed medical cannabis companies
within 18 months and have potential for drug delivery applications
far beyond cannabinoids.
Promising Pipeline
Not a one-trick-pony, PreveCeutical has already brought one
product to market and is developing a diverse portfolio of research
and development programs that address large market diseases.
PreveCeutical Medical’s first commercial product, CELLB9®, is an
oral dilute solution infused with select peptides and proteins
isolated from Caribbean Blue Scorpion venom. The active ingredients
in CELLB9 have been used around the world for over 25 years and
have generated volumes of anecdotal reports about their efficacy.
PreveCeutical’s research team is now using proprietary chemistry to
generate Nature Identical™ peptides (http://nnw.fm/B9bBj) for a range of ailments.
PreveCeutical and its Australian research commercialization
partner, UniQuest, are currently screening these peptides for use
against some of the most aggressive diseases where there exist
unmet clinical needs.
In conjunction with leading Australian research centers,
PreveCeutical is also pursuing dual-gene therapy research as both a
preventative measure and possible treatment for type 2 diabetes and
obesity. Over five years of multi-disciplinary research has
generated convincing results in disease models that a single gene
may be implicated in Type 2 diabetes and obesity. PreveCeutical’s
gene-silencing technology would effectively turn off the genetic
signal that leads to the over-production of a key protein molecule,
in turn reducing blood sugar levels and preventing the body from
storing excessive fat. As Dr. Parekh stated in a press release,
“…gene-silencing does not represent a mere management for diabetes
and obesity, it represents the potential for a bona fide cure…”
In what may be a quantum leap in addressing the critical demand
for non-additive pain medications, PreveCeutical and its partner
UniQuest are expanding the use of their disulphide linker
technology to develop non-addictive analgesics for
moderate-to-severe pain (http://nnw.fm/4TQgv). The four-phase research program
will be led by Dr. Parekh and carried out in collaboration with
pain and inflammation pharmacology experts at the University of
Queensland.
PreveCeutical’s pain program is of considerable importance in
light of America’s opioid epidemic. As the National Institute on
Drug Abuse reports, prescription opioid abuse costs the United
States more than $78 billion per year. The loss of life is even
more devastating, with more than 115 Americans dying from opioid
overdose each day (http://nnw.fm/7nExT).
Read more on PreveCeutical’s pain program in this editorial
entitled, ‘Promising New Approaches in Pain Management’: http://nnw.fm/3tQ5s.
Others Leading Delivery Platforms
Recognizable household brand Johnson & Johnson
(NYSE: JNJ) also has its hand in hydrogel technology. In
July 2016 the company’s Johnson & Johnson Vision Care, Inc.
launched its silicone hydrogel contact lens, Acuvue Vita. As noted
in a press release, the design of Acuvue Vita addressed contact
lens wearer discomfort by increasing hydration, thanks to “a
noncoated silicone hydrogel material that maximizes and maintains
hydration all month long” (http://nnw.fm/4ArJ9). In April 2017, Johnson &
Johnson released Acuvue Vita for monthly wear, and provided some
insight into its HydraMax technology (http://nnw.fm/Tt31U).
Valeant Pharmaceuticals (NYSE: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorders,
eye health, neurology and branded generics. Through its wholly
owned subsidiary, Bausch + Lomb, a leading global eye health
company, Valeant Pharmaceuticals introduced an innovative bi-weekly
silicone hydrogel contact lens that helps the lens maintain 95
percent of its moisture up to a full 16 hours and provides patients
maximum comfort throughout the day. In another example of hydrogel
efficacy, silicone hydrogel lenses allow significantly more oxygen
to reach the eye than regular soft lenses.
UroGen Pharma (NASDAQ: URGN), is a
clinical-stage biopharmaceutical company developing treatments to
address unmet needs in the field of urology. Its RTGel™ product is
a proprietary, sustained-release hydrogel-based formulation
designed for potentially improving therapeutic profiles of existing
drugs. BotuGel is the company’s proprietary RTGel-based formulation
of Allergan Pharmaceuticals’ BOTOX® branded drug, as a potential
treatment option for overactive bladder (http://nnw.fm/5nHPn).
Though not involved with hydrogels, biopharmaceutical company
GW Pharmaceuticals (NASDAQ: GWPH) demonstrates the
market demand and opportunity for advanced drug delivery systems.
GW Pharmaceuticals develops and commercializes novel therapeutics
from its proprietary cannabinoid product platform. Among the drugs
in its portfolio is Sativex, a medicinal cannabis extract indicated
for the relief of multiple sclerosis symptoms and the treatment of
severe neuropathic-related cancer pain. For efficacious delivery of
Sativex, GW also patented a metered valve pump spray device to
deliver its liquid cannabis extract, in propylene glycol and
ethanol, for dosing of a patient’s sublingual mucosa. Sativex
oromucosal spray has been approved for use in 30 countries outside
the United States.
To accommodate advances in pharmaceutical development, the
practice of drug delivery has changed dramatically over the past
few decades. Even greater changes are expected as innovative new
therapeutics are discovered. Innovative pharmaceutical treatments
require innovative methods of administration, and the companies
that develop these new delivery platforms have the potential to see
rapid appreciation.
For more information on PreveCeutical, visit PreveCeutical
Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible, (2) article and editorial syndication to
5,000+ news outlets (3), enhanced press release services to ensure
maximum impact, (4) social media distribution via the Investor
Brand Network (IBN) to nearly 2 million followers, (5) a full array
of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a
multifaceted organization with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
PreveCeutical Medical (QB) (USOTC:PRVCF)
Historical Stock Chart
From Oct 2024 to Nov 2024
PreveCeutical Medical (QB) (USOTC:PRVCF)
Historical Stock Chart
From Nov 2023 to Nov 2024
